Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P trimmed its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 7.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,809 shares of the biopharmaceutical company’s stock after selling 5,200 shares during the quarter. Martingale Asset Management L P owned 0.11% of Vanda Pharmaceuticals worth $310,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of VNDA. Verition Fund Management LLC boosted its position in shares of Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Vanda Pharmaceuticals by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock worth $2,796,000 after purchasing an additional 3,473 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Vanda Pharmaceuticals by 8.8% during the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 4,449 shares during the period. Brandywine Global Investment Management LLC grew its stake in shares of Vanda Pharmaceuticals by 13.9% in the fourth quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 4,820 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 5,459 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Trading Up 1.2 %

Vanda Pharmaceuticals stock opened at $4.13 on Monday. The firm has a market capitalization of $240.85 million, a P/E ratio of -12.91 and a beta of 0.72. The stock’s fifty day simple moving average is $4.62 and its 200-day simple moving average is $4.69. Vanda Pharmaceuticals Inc. has a twelve month low of $3.85 and a twelve month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was bought at an average cost of $5.02 per share, with a total value of $50,200.00. Following the acquisition, the chief executive officer now directly owns 2,285,731 shares of the company’s stock, valued at approximately $11,474,369.62. This represents a 0.44 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders bought 32,000 shares of company stock worth $151,180 in the last 90 days. Corporate insiders own 8.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on VNDA shares. StockNews.com began coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, April 1st.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.